Japan Tissue Engineering Co

Japan Tissue Engineering Co Dividend

Dividend of Japan Tissue Engineering Co (7774.T) as of Oct 22, 2026.

Dividend

0.00JPY

Last updated:

How much dividend does Japan Tissue Engineering Co 2026 pay?

According to the latest status from October 2026, Japan Tissue Engineering Co paid a total of 0.00 JPY per share in dividends within the last 12 months. With the current Japan Tissue Engineering Co price of 723.00 JPY, this corresponds to a dividend yield of - %. A dividend is paid times per year.

Historical Japan Tissue Engineering Co Dividends

Historical Japan Tissue Engineering Co Dividends
PaydateDividend

The Japan Tissue Engineering Co Dividend history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Dividend
Date
Dividend
Jan 1, 2022
0.00 JPY
Jan 1, 2023
0.00 JPY
Jan 1, 2024
0.00 JPY
Jan 1, 2025
0.00 JPY
Jan 1, 2026
0.00 JPY
Jan 1, 2027 (e)
0.00 JPY
Jan 1, 2028 (e)
0.00 JPY
Jan 1, 2029 (e)
0.00 JPY
The Japan Tissue Engineering Co Dividend history
YEARDividendYoY
est0.00JPY—
est0.00JPY—
est0.00JPY—
0.00JPY—
0.00JPY—
0.00JPY—
0.00JPY—
0.00JPY—
0.00JPY—
0.00JPY—
0.00JPY—
0.00JPY—
0.00JPY—
0.00JPY—
0.00JPY—
0.00JPY—
0.00JPY—
0.00JPY—
0.00JPY—
0.00JPY—
0.00JPY—
0.00JPY—
0.00JPY—

Is the Japan Tissue Engineering Co Dividend Safe?

Japan Tissue Engineering Co has been increasing the dividend for 0 years.

Analysts expect a Dividend Cut of -100.00% for the current fiscal year.

Dividend Details

Understanding Japan Tissue Engineering Co's Dividend Distributions

Japan Tissue Engineering Co’s dividends are a portion of the company’s profits distributed to shareholders. It is a critical indicator of the company’s financial health and attractiveness to investors. Dividends provide investors with a steady income stream, in addition to any profits that may come from selling the stock at a higher price than the purchase price.

Year-to-Year Comparison

Examining Japan Tissue Engineering Co's dividend distributions over the years can highlight the company’s profitability and stability. A consistent or increasing dividend payout can indicate a financially healthy company with predictable earnings, while fluctuations or reductions in dividends can suggest underlying financial or operational challenges.

Impact on Investments

Japan Tissue Engineering Co's dividend payments are an essential factor for income-focused investors. A robust dividend payout can enhance the stock’s appeal, offering regular income in addition to potential capital gains. It also can indicate the company's confidence in its future earnings, making it a significant consideration in investment decisions.

Interpreting Dividend Fluctuations

Changes in Japan Tissue Engineering Co’s dividends can result from shifts in the company’s earnings, financial policies, or reinvestment strategies. An increase in dividends often signals financial stability, while a decrease may indicate a need to conserve cash or reinvest profits to fuel growth, each scenario having different implications for investors.

Japan Tissue Engineering Co Stock analysis

What does Japan Tissue Engineering Co do? Japan Tissue Engineering Co., Ltd. generates revenue through three business segments. The Regenerative Medicine Product segment sells autologous cultured epidermis JACE and autologous cultured cartilage JACK to medical institutions. The Regenerative Medicine Outsourcing segment offers CDMO, CRO, consulting, and contract manufacturing services for cell processed products. The Research and Development Support segment sells human cultured tissues developed using the company's advanced culture technology. Medical institutions purchase regenerative medicine products, while pharmaceutical and biotech companies utilize outsourcing services for cell-based therapies. The company's products are sold to healthcare providers and research-focused clients across Japan and potentially internationally. The Regenerative Medicine Product segment focuses on selling JACE and JACK, which are used in medical treatments requiring tissue regeneration. These products are specifically designed for autologous use, meaning they are derived from the patient's own cells. The Outsourcing segment provides specialized services to support the development and manufacturing of cell-based therapies, targeting pharmaceutical and biotech firms. The Research and Development Support segment supplies tissues for research applications, leveraging the company's internal technology to meet client needs in scientific development. JACE and JACK are key products in the Regenerative Medicine Product segment, directly sold to medical institutions for clinical use. The Outsourcing segment serves as a service provider for cell therapy development, offering CDMO and CRO capabilities. The Research and Development Support segment's human cultured tissues are marketed to research organizations seeking advanced cell culture solutions. All segments contribute to the company's revenue by addressing specific needs in regenerative medicine and cell therapy development. Japan Tissue Engineering Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Japan Tissue Engineering Co stock

Japan Tissue Engineering Co paid dividends every year for the past 0 years.

Japan Tissue Engineering Co is assigned to the 'Health' sector.

The dividends of Japan Tissue Engineering Co are distributed in JPY.

Dividend calendar 2026

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

All Key Metrics — Japan Tissue Engineering Co